Functional and morphological examinations of P1A1 purinoceptors in the normal and inflamed urinary bladder of the rat

Autonomic Neuroscience: Basic and Clinical

Volumn 159, Issue 1-2, 2011, Pages 26-31

  Vesela, Renata ^a,b   Aronsson, Patrik ^b   Tobin, Gunnar ^b  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Cystitis; P1; Purinergic; Purinoceptor; Rat urinary bladder

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 6 ETHYL 2 PHENYL 4 PROPYL 3 PYRIDINECARBOXYLIC ACID 5 THIOCARBOXYLIC ACID 5 ETHYL 3 PROPYL ESTER; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE; ADENOSINE RECEPTOR; CYCLOPHOSPHAMIDE; MUSCLE RELAXANT AGENT; PURINERGIC P1A1 RECEPTOR; PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYSTITIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MUSCLE CONTRACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ADENOSINE; ANIMALS; CYSTITIS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; INFLAMMATION MEDIATORS; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PURINERGIC P1 RECEPTOR AGONISTS; PURINERGIC P1 RECEPTOR ANTAGONISTS; PURINERGIC P2 RECEPTOR ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A1; URINARY BLADDER;

EID: 78649904257     PISSN: 15660702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autneu.2010.07.008     Document Type: Article

References (43)

1. Andersson K.E. Overactive bladder-pharmacological aspects. Scand. J. Urol. Nephrol. Suppl. 2002, 72-81.
2. Andersson K.E., Hedlund P. Pharmacologic perspective on the physiology of the lower urinary tract. Urology 2002, 60:13-20. discussion 20-11.
3. Andersson M.C., Tobin G., Giglio D. Cholinergic nitric oxide release from the urinary bladder mucosa in cyclophosphamide-induced cystitis of the anaesthetized rat. Br. J. Pharmacol. 2008, 153:1438-1444.
4. Ansari H.R., Nadeem A., Tilley S.L., Mustafa S.J. Involvement of COX-1 in A3 adenosine receptor-mediated contraction through endothelium in mice aorta. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H3448-3455.
5. Aronsson P., Andersson M., Ericsson T., Giglio D. Assessment and characterization of purinergic contractions and relaxations in the rat urinary bladder. Basic Clin. Pharmacol. Toxicol. 2010, 107:603-613.
6. Bailey S.J., Hourani S.M. Differential effects of suramin on P2-purinoceptors mediating contraction of the guinea-pig vas deferens and urinary bladder. Br. J. Pharmacol. 1994, 112:219-225.
7. Batista C.K., Brito G.A., Souza M.L., Leitao B.T., Cunha F.Q., Ribeiro R.A. A model of hemorrhagic cystitis induced with acrolein in mice. Braz. J. Med. Biol. Res. 2006, 39:1475-1481.
8. Belardinelli L., Shryock J.C., Snowdy S., Zhang Y., Monopoli A., Lozza G., Ongini E., Olsson R.A., Dennis D.M. The A2A adenosine receptor mediates coronary vasodilation. J. Pharmacol. Exp. Ther. 1998, 284:1066-1073.
9. Birder L.A., Ruan H.Z., Chopra B., Xiang Z., Barrick S., Buffington C.A., Roppolo J.R., Ford A.P., de Groat W.C., Burnstock G. Alterations in P2X and P2Y purinergic receptor expression in urinary bladder from normal cats and cats with interstitial cystitis. Am. J. Physiol. Renal. Physiol. 2004, 287:F1084-1091.
10. Bucheimer R.E., Linden J. Purinergic regulation of epithelial transport. J. Physiol. 2004, 555:311-321.
11. Burnstock G., Dumsday B., Smythe A. Atropine resistant excitation of the urinary bladder: the possibility of transmission via nerves releasing a purine nucleotide. Br. J. Pharmacol. 1972, 44:451-461.
12. Chen B.C., Lee C.M., Lin W.W. Inhibition of ecto-ATPase by PPADS, suramin and reactive blue in endothelial cells, C6 glioma cells and RAW 264.7 macrophages. Br. J. Pharmacol. 1996, 119:1628-1634.
13. Cox P.J. Cyclophosphamide cystitis and bladder cancer. A hypothesis. Eur. J. Cancer 1979, 15:1071-1072.
14. Dang K., Lamb K., Cohen M., Bielefeldt K., Gebhart G.F. Cyclophosphamide-induced bladder inflammation sensitizes and enhances P2X receptor function in rat bladder sensory neurons. J. Neurophysiol. 2008, 99:49-59.
15. Feoktistov I., Biaggioni I. Adenosine A2B receptors. Pharmacol. Rev. 1997, 49:381-402.
16. Ford A.P., Gever J.R., Nunn P.A., Zhong Y., Cefalu J.S., Dillon M.P., Cockayne D.A. Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br. J. Pharmacol. 2006, 147(Suppl 2):S132-143.
17. Gao Z., Li B.S., Day Y.J., Linden J. A3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. Mol. Pharmacol. 2001, 59:76-82.
18. Gessi S., Merighi S., Varani K., Leung E., Mac Lennan S., Borea P.A. The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol. Ther. 2008, 117:123-140.
19. Giglio D., Tobin G. Muscarinic receptor subtypes in the lower urinary tract. Pharmacology 2009, 83:259-269.
20. Giglio D., Delbro D.S., Tobin G. On the functional role of muscarinic M2 receptors in cholinergic and purinergic responses in the rat urinary bladder. Eur. J. Pharmacol. 2001, 428:357-364.
21. Giglio D., Ryberg A.T., To K., Delbro D.S., Tobin G. Altered muscarinic receptor subtype expression and functional responses in cyclophosphamide induced cystitis in rats. Auton. Neurosci. 2005, 122:9-20.
22. Haleen S.J., Steffen R.P., Hamilton H.W. PD 116, 948, a highly selective A1 adenosine receptor antagonist. Life Sci. 1987, 40:555-561.
23. Hasko G., Cronstein B.N. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004, 25:33-39.
24. Hasko G., Linden J., Cronstein B., Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov. 2008, 7:759-770.
25. Hegde S.S., Choppin A., Bonhaus D., Briaud S., Loeb M., Moy T.M., Loury D., Eglen R.M. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br. J. Pharmacol. 1997, 120:1409-1418.
26. King B.F., Knowles I.D., Burnstock G., Ramage A.G. Investigation of the effects of P2 purinoceptor ligands on the micturition reflex in female urethane-anaesthetized rats. Br. J. Pharmacol. 2004, 142:519-530.
27. Lambrecht G. Agonists and antagonists acting at P2X receptors: selectivity profiles and functional implications. Naunyn Schmiedebergs Arch. Pharmacol. 2000, 362:340-350.
28. Lambrecht G., Friebe T., Grimm U., Windscheif U., Bungardt E., Hildebrandt C., Baumert H.G., Spatz-Kumbel G., Mutschler E. PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses. Eur. J. Pharmacol. 1992, 217:217-219.
29. Lee K.S., Reddington M. 1, 3-Dipropyl-8-cyclopentylxanthine (DPCPX) inhibition of [3H]N-ethylcarboxamidoadenosine (NECA) binding allows the visualization of putative non-A1 adenosine receptors. Brain Res. 1986, 368:394-398.
30. Logadottir Y.R., Ehren I., Fall M., Wiklund N.P., Peeker R., Hanno P.M. Intravesical nitric oxide production discriminates between classic and nonulcer interstitial cystitis. J. Urol. 2004, 171:1148-1150. discussion 1150-1141.
31. McMurray G., Dass N., Brading A.F. Purinoceptor subtypes mediating contraction and relaxation of marmoset urinary bladder smooth muscle. Br. J. Pharmacol. 1998, 123:1579-1586.
32. Mitchell C.H., Peterson-Yantorno K., Carre D.A., McGlinn A.M., Coca-Prados M., Stone R.A., Civan M.M. A3 adenosine receptors regulate Cl- channels of nonpigmented ciliary epithelial cells. Am. J. Physiol. 1999, 276:C659-666.
33. Modis K., Gero D., Nagy N., Szoleczky P., Toth Z.D., Szabo C. Cytoprotective effects of adenosine and inosine in an in vitro model of acute tubular necrosis. Br. J. Pharmacol. 2009, 158:1565-1578.
34. Säve, S. 2010. ATP and adenosine in experimental urinary tract infection, Vol. PhD. Linneus University. pp. 1-59.
35. Save S., Mjosberg J., Poljakovic M., Mohlin C., Persson K. Adenosine receptor expression in Escherichia coli-infected and cytokine-stimulated human urinary tract epithelial cells. BJU Int. 2009, 104:1758-1765.
36. Sitkovsky M.V., Lukashev D., Apasov S., Kojima H., Koshiba M., Caldwell C., Ohta A., Thiel M. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu. Rev. Immunol. 2004, 22:657-682.
37. Sjogren C., Andersson K.E., Husted S., Mattiasson A., Moller-Madsen B. Atropine resistance of transmurally stimulated isolated human bladder muscle. J. Urol. 1982, 128:1368-1371.
38. Sun Y., Chai T.C. Augmented extracellular ATP signaling in bladder urothelial cells from patients with interstitial cystitis. Am. J. Physiol. Cell Physiol. 2006, 290:C27-34.
39. Tobin G., Sjogren C. In vivo and in vitro effects of muscarinic receptor antagonists on contractions and release of [3H]acetylcholine in the rabbit urinary bladder. Eur. J. Pharmacol. 1995, 281:1-8.
40. Volpini R., Costanzi S., Vittori S., Cristalli G., Klotz K.N. Medicinal chemistry and pharmacology of A2B adenosine receptors. Curr. Top. Med. Chem. 2003, 3:427-443.
41. Wang E.C., Lee J.M., Ruiz W.G., Balestreire E.M., von Bodungen M., Barrick S., Cockayne D.A., Birder L.A., Apodaca G. ATP and purinergic receptor-dependent membrane traffic in bladder umbrella cells. J. Clin. Invest. 2005, 115:2412-2422.
42. Yu W., Zacharia L.C., Jackson E.K., Apodaca G. Adenosine receptor expression and function in bladder uroepithelium. Am. J. Physiol. Cell Physiol. 2006, 291:C254-265.
43. Zocchi C., Ongini E., Conti A., Monopoli A., Negretti A., Baraldi P.G., Dionisotti S. The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist. J. Pharmacol. Exp. Ther. 1996, 276:398-404.